Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AMG 199 in MUC17-Positive Solid Tumors
jRCT2080225224Phase 1Terminated
- Sponsor
- Amgen
- Start
- Jun 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of amg 199 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer (CRC) and 1 more, sponsored by Amgen. Primary endpoints: Safety and tolerability of AMG 199, Pharmacokinetics of AMG 199 and 1 more. Started Jun 2020; status: terminated.
02
Drugs
amg 199
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080225224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225224.